References
1. Eriksson J, Ekerljung L, Rönmark E, et al. Update of prevalence of
self-reported allergic rhinitis and chronic nasal symptoms among adults
in Sweden. The clinical respiratory journal. 2012;6(3):159-168.
2. Warm K, Hedman L, Lindberg A, Lötvall J, Lundback B, Rönmark E.
Allergic sensitization is age-dependently associated with rhinitis, but
less so with asthma. The Journal of allergy and clinical
immunology. 2015;136(6):1559-1565.e1551-1552.
3. Newson RB, van Ree R, Forsberg B, et al. Geographical variation in
the prevalence of sensitization to common aeroallergens in adults: the
GA(2) LEN survey. Allergy. 2014;69(5):643-651.
4. Cardell LO, Olsson P, Andersson M, et al. TOTALL: high cost of
allergic rhinitis-a national Swedish population-based questionnaire
study. NPJ primary care respiratory medicine. 2016;26:15082.
5. Di Bona D, Bilancia M, Albanesi M, Caiaffa MF, Macchia L.
Cost-effectiveness of grass pollen allergen immunotherapy in adults.Allergy. 2020.
6. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and
immune tolerance to allergens. The World Allergy Organization
journal. 2015;8(1):17.
7. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen
Immunotherapy: Allergic rhinoconjunctivitis. Allergy.2018;73(4):765-798.
8. Klimek L, Pfaar O, Bousquet J, Senti G, Kundig T. Allergen
immunotherapy in allergic rhinitis: current use and future trends.Expert review of clinical immunology. 2017;13(9):897-906.
9. Hoffmann HJ, Valovirta E, Pfaar O, et al. Novel approaches and
perspectives in allergen immunotherapy. Allergy.2017;72(7):1022-1034.
10. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for
allergic rhinoconjunctivitis: A systematic review and meta-analysis.Allergy. 2017;72(11):1597-1631.
11. Arvidsson MB, Löwhagen O, Rak S. Effect of 2-year placebo-controlled
immunotherapy on airway symptoms and medication in patients with birch
pollen allergy. The Journal of allergy and clinical immunology.2002;109(5):777-783.
12. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for
allergic rhinitis? Journal of Allergy and Clinical Immunology.2016;137(2):339-349.e310.
13. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic
allergen administration renders specific immunotherapy faster and safer:
a randomized controlled trial. Proc Natl Acad Sci U S A.2008;105(46):17908-17912.
14. Patterson AM, Bonny AE, Shiels WE, 2nd, Erwin EA. Three-injection
intralymphatic immunotherapy in adolescents and young adults with grass
pollen rhinoconjunctivitis. Annals of allergy, asthma &
immunology : official publication of the American College of Allergy,
Asthma, & Immunology. 2016;116(2):168-170.
15. Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ.
Intralymphatic immunotherapy induces allergen specific plasmablasts and
increases tolerance to skin prick testing in a pilot study.Clinical and translational allergy. 2016;6:19.
16. Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic
immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind
placebo-controlled trial. Respir Res. 2016;17:10.
17. Hellkvist L, Hjalmarsson E, Kumlien Georen S, et al. Intralymphatic
immunotherapy with 2 concomitant allergens, birch and grass: A
randomized, double-blind, placebo-controlled trial. The Journal of
allergy and clinical immunology. 2018;142(4):1338-1341 e1339.
18. Ahlbeck L, Ahlberg E, Nyström U, Björkander J, Jenmalm MC.
Intralymphatic allergen immunotherapy against pollen allergy: A 3-year
open follow-up study of 10 patients. Annals of allergy, asthma &
immunology : official publication of the American College of Allergy,
Asthma, & Immunology. 2018;121(5):626-627.
19. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is
intralymphatic immunotherapy ready for clinical use in patients with
grass pollen allergy? The Journal of allergy and clinical
immunology. 2013;132(5):1248-1252 e1245.
20. Senti G, Freiburghaus AU, Larenas-Linnemann D, et al. Intralymphatic
Immunotherapy: Update and Unmet Needs. International archives of
allergy and immunology. 2019;178(2):141-149.
21. Devillier P, Chassany O, Vicaut E, et al. The minimally important
difference in the Rhinoconjunctivitis Total Symptom Score in
grass-pollen-induced allergic rhinoconjunctivitis. Allergy.2014;69(12):1689-1695.
22. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the
standardized version of the Rhinoconjunctivitis Quality of Life
Questionnaire. The Journal of allergy and clinical immunology.1999;104(2 Pt 1):364-369.
23. Fauquert J-L, Jedrzejczak-Czechowicz M, Rondon C, et al.
Conjunctival allergen provocation test : guidelines for daily practice.Allergy. 2017;72(1):43-54.
24. Pfaar O, Agache I, Bergmann K, et al. Placebo effects in allergen
immunotherapy – an EAACI Task Force Position Paper.Allergy. n/a(n/a).
25. Freiberger SN, Zehnder M, Gafvelin G, Grönlund H, Kündig TM,
Johansen P. IgG4 but no IgG1 antibody production after intralymphatic
immunotherapy with recombinant MAT-Feld1 in human. Allergy.2016;71(9):1366-1370.
26. Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety
requirements for diagnostic and therapeutic procedures in allergology:
World Allergy Organization Statement. The World Allergy
Organization journal. 2016;9(1):33.
27. Schiappoli M, Ridolo E, Senna G, et al. A prospective Italian survey
on the safety of subcutaneous immunotherapy for respiratory allergy.Clinical and experimental allergy : journal of the British Society
for Allergy and Clinical Immunology. 2009;39(10):1569-1574.
28. Aasbjerg K, Dalhoff KP, Backer V. Adverse Events During
Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis -
Differences Between Subcutaneous and Sublingual Treatment. Basic
Clin Pharmacol Toxicol. 2015;117(2):73-84.
29. Bousquet J, Schünemann HJ, Bousquet PJ, et al. How to design and
evaluate randomized controlled trials in immunotherapy for allergic
rhinitis: an ARIA-GA(2) LEN statement. Allergy.2011;66(6):765-774.
30. Wagenmann M, Worm M, Akboga Y, Karjalainen M, Hohlfeld JM.
Randomized immunotherapy trial in dual-allergic patients using ”active
allergen placebo” as control. Allergy. 2019;74(8):1480-1489.
31. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy
has long-term preventive effect of seasonal and perennial asthma:
10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948.
32. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the
5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP)
trial in children with grass pollen allergy. The Journal of
allergy and clinical immunology. 2018;141(2):529-538.e513.
33. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention
of new sensitizations in asthmatic children monosensitized to house dust
mite by specific immunotherapy. A six-year follow-up study.Clinical and experimental allergy : journal of the British Society
for Allergy and Clinical Immunology. 2001;31(9):1392-1397.
34. Bender BG, Oppenheimer J. The special challenge of nonadherence with
sublingual immunotherapy. The journal of allergy and clinical
immunology In practice. 2014;2(2):152-155.
35. Hedenström H, Malmberg P, Fridriksson HV. Reference values for lung
function tests in men: regression equations with smoking variables.Upsala journal of medical sciences. 1986;91(3):299-310.
36. Hedenström H, Malmberg P, Agarwal K. Reference values for lung
function tests in females. Regression equations with smoking variables.Bulletin europeen de physiopathologie respiratoire.1985;21(6):551-557.
37. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and
differentiation dynamics of human CD4+ T cells expressing the FoxP3
transcription factor. Immunity. 2009;30(6):899-911.
38. Jenmalm MC, Björksten B, Macaubas C, Holt BJ, Smallacombe TB, Holt
PG. Allergen-induced cytokine secretion in relation to atopic symptoms
and immunoglobulin E and immunoglobulin G subclass antibody responses.Pediatric allergy and immunology : official publication of the
European Society of Pediatric Allergy and Immunology.1999;10(3):168-177.
39. Forsberg A, Abrahamsson TR, Björksten B, Jenmalm MC. Pre- and
post-natal Lactobacillus reuteri supplementation decreases allergen
responsiveness in infancy. Clinical and experimental allergy :
journal of the British Society for Allergy and Clinical Immunology.2013;43(4):434-442.
TABLE 1 Baseline characteristics by treatment group, presented
as mean and standard deviation